Showing results (91-100 of 125) with videos related to
Sort By:
Pageof 13
EJNMMI Radiopharmacy and Chemistry|December 31, 2025
Assessment of quality control and effect of radiolysis on the in vivo biodistribution of [<sup>177</sup>Lu]Lu-PSMA-I&TEline L Hooijman, Carolline M Ntihabose, Stijn L W Koolen, et al.Journal for Immunotherapy of Cancer|May 29, 2020
Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancerDaan P Hurkmans, Edwin A Basak, Nina Schepers, et al.Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 3, 2025
Drug release from docetaxel-entrapped core-crosslinked polymeric micelles: A population pharmacokinetic modelling approach based on clinical dataPascale C S Rietveld, Stijn L W Koolen, Stefan Zeiser, et al.Thyroid : Official Journal of the American Thyroid Association|March 11, 2020
Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer PatientsEdwin A Basak, Jan W M van der Meer, Daan P Hurkmans, et al.Pharmaceutics|August 23, 2020
Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of SorafenibKoen G A M Hussaarts, Leni van Doorn, Karel Eechoute, et al.Clinical Pharmacokinetics|November 17, 2021
Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast CancerC Louwrens Braal, Agnes Jager, Esther Oomen-de Hoop, et al.Ebiomedicine|March 20, 2024
Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysisSophie M Ernst, Maaike M Hofman, Tessa E van der Horst, et al.Journal for Immunotherapy of Cancer|June 5, 2021
Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumorsDaan P Hurkmans, Sebastiaan D T Sassen, Karlijn de Joode, et al.British Journal of Cancer|November 10, 2022
Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertensionLeni van Doorn, Wesley J Visser, Daan C H van Dorst, et al.Drugs|January 12, 2023
Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface MalignanciesNiels A D Guchelaar, Bo J Noordman, Stijn L W Koolen, et al.Pageof 13